PRAX vs UNH

Praxis Precision Medicines continues to advance its promising CNS pipeline, notably with the presumed NDA submission for PRAX-118 by end of 2025, a significant de-risking event reflected in its increased market cap to $8.97B. The company targets large, underserved markets (Essential Tremor, Epilepsies) with strong IP and novel mechanisms. While financial health remains a key watchpoint as a pre-co...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...